程序性死亡受体1/程序性死亡受体配体1抑制剂联合安罗替尼在广泛期小细胞肺癌维持治疗中的应用  

Application of programmed cell death 1/programmed cell death 1 ligand 1 inhibitor combined with anlotinib in the maintenance treatment of extensive stage small cell lung cancer

作　　者：徐芸 张鸿博 王代勇 郑文 XU Yun;ZHANG Hongbo;WANG Daiyong;ZHENG Wen(Department of Oncology,2Department of Respiratory and Critical Care Medicine,3Department of Thoracic Surgery,Shangrao People’sHospital,Shangrao 334000,Jiangxi,China)

机构地区：[1]上饶市人民医院肿瘤内科,江西上饶3340000 [2]上饶市人民医院呼吸与危重症医学科,江西上饶3340000 [3]上饶市人民医院胸外科,江西上饶3340000

出　　处：《癌症进展》2024年第10期1113-1116,共4页Oncology Progress

基　　金：上饶市科技计划项目(2023CZDX171)。

摘　　要：目的 探讨程序性死亡受体1(PD-1)/程序性死亡受体配体1(PD-L1)抑制剂联合安罗替尼在广泛期小细胞肺癌(ES-SCLC)维持治疗中的疗效及安全性。方法 采用信封法将80例ES-SCLC患者随机分为联合组(40例)和对照组(40例)。对照组患者采用PD-1/PD-L1抑制剂联合依托泊苷+铂类(EP)方案一线治疗后使用PD-1/PD-L1抑制剂维持治疗,联合组患者在对照组的基础上联合盐酸安罗替尼胶囊维持治疗。比较两组患者的客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)及不良反应发生情况。结果 联合组患者ORR、DCR均高于对照组,中位PFS和中位OS均长于对照组,差异均有统计学意义(P﹤0.05)。两组患者不良反应主要以1~2级为主,各不良反应发生率比较,差异均无统计学意义(P﹥0.05)。结论 PD-1/PD-L1抑制剂联合安罗替尼用于ES-SCLC患者维持治疗效果显著,能有效延长患者PFS和OS,且并未增加不良反应。Objective To investigate the efficacy and safety of programmed cell death 1(PD-1)/programmed cell death 1 ligand 1(PD-L1)inhibitors combined with anlotinib in the maintenance treatment of extensive stage small cell lung cancer(ES-SCLC).Method A total of 80 patients with ES-SCLC were randomly divided into combination group(40 cases)and control group(40 cases)by envelope method.The control group was treated with PD-1/PD-L1 inhibitor combined with etoposide+platinum(EP)regimen after the first-line treatment,and the combined group was treated with anlotinib hydrochloride capsule on the basis of the control group.Objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS)and adverse reactions were compared between the two groups.Result The ORR and DCR in combination group were higher than those in control group,and the median PFS and median OS were longer than those in control group,the differences were statistically significant(P<0.05).The ad-verse reactions of the two groups were mainly grade 1 to grade 2,and there were no statistical significances in the inci-dence of adverse reactions between the two groups(P>0.05).Conclusion PD-1/PD-L1 inhibitor combined with anlo-tinib is effective in maintenance treatment of patients with ES-SCLC,and can effectively prolong patients’PFS and OS without increasing adverse reactions.

关 键 词：程序性死亡受体1/程序性死亡受体配体1 安罗替尼 广泛期小细胞肺癌 维持治疗 

分 类 号：R734.2[医药卫生—肿瘤]